CDER’s Office of Pharmaceutical Quality created the Emerging Technology Program to promote the adoption of innovative approaches to pharmaceutical product design and manufacturing.
Similar Posts
Plastikon Healthcare Issues Voluntary Nationwide Recall of Milk of Magnesia Oral Suspension and Magnesium Hydroxide /Aluminum Hydroxide /Simethicone Oral Suspension Due to Microbial Contamination
Lawrence, Kansas – Plastikon Healthcare, LLC is voluntarily recalling one (1) lot of Milk of Magnesia 2400 mg/10 mL Oral Suspension, one (1) lot of Milk of Magnesia 2400 mg/30 mL Oral Suspension, eleven (11) lots of Magnesium Hydroxide 1200 mg/Aluminum Hydroxide 1200 mg/Simethicone 120 mg per 30 mLCompounding and the FDA: Questions and Answers
Creating a medication tailored to the needs of an individual patient. FDA answers the “what” and “why” of compounding. From consumers to health care professionals, there are many questions about compounding. FDA works to answer questions related to the meaning, intent and requirements of compoundingDollar General Announces Voluntary Recall of Clover Valley® Instant Coffee Due to Potential Presence of Glass
Goodlettsville, Tennessee – August 11, 2025 –Dollar General Corporation is recalling three (3) lots of its eight (8) ounce Clover Valley® Instant Coffee due to the potential presence of glass.AlzClipp / UniUni – 711274 – 07/29/2025
Unapproved New Drugs/MisbrandedConcord Biotech Limited – 04/28/2025-05/02/2025
Concord Biotech Limited – 04/28/2025-05/02/2025. Country: India. Record Type: 483Advisory Letters
Advisory Letters